EUCTR2007-004452-36-ES进行中（未招募）不适用
Estudio multicéntrico, doble ciego, controlado con placebo y de grupos paralelos para evaluar la eficacia y seguridad de teriflunomida en pacientes con esclerosis múltiple recurrente_________________________________________________________________A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis - TOWER
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with relapsing forms of Multiple Sclerosis meeting McDonald’s criteria for MS diagnosis at time of screening, and EDSS scores of = 5.5 at screening.
- •Experienced at least 1 relapse in the previous 12 months preceeding randomization, or at least 2 relapses in the 24 months preceeding randomization visit.
- •Patients who Have provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of approved therapies available for relapsing forms of MS. The patient must have been offered these therapies and must choose to join the study instead of accepting therapy outside of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •<18 years of age or =56 years of age
- •Patients with significantly impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia
- •Persistent significant or severe infection
- •Liver function impairment or persisting elevations (confirmed by retest) of serum glutamic pyruvic transaminase (SGPT/ALT), serum glutamic oxaloacetic transaminase (SGOT/AST), or direct bilirubin greater than 1.5-fold the upper limit of normal
- •Known history of hepatitis
- •Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 2 weeks prior to randomization
- •Human immunodeficiency virus (HIV) positive patients
- •Prior or concomitant use of cladribine, mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporin, methotrexate or mycophenolate
- •Prior or concomitant use of natalizumab (Tysabri®)
- •Pregnant or breast-feeding women
研究者
相似试验
进行中（未招募）
不适用
Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos para evaluar la eficacia y seguridad de la teriflunomida en pacientes con esclerosis múltiple recurrente que están en tratamiento con interferón-beta____________A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta. - TERACLESEsclerosis múltiple_______Multiple sclerosisMedDRA version: 12.1Level: LLTClassification code 10028245Term: Multiple sclerosisEUCTR2010-023172-12-ESsanofi-aventis recherche et development1,455
进行中（未招募）
1 期
Estudio multicéntrico, doble ciego, controlado con placebo, de grupos paralelos, fase IV para evaluar el efecto de rotigotina sobre los síntomas no motores en pacientes con enfermedad de Parkinson idiopática(Multicenter, double-blind, placebo controlled, parallel-group, phase IV study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic parkinsons disease) - SP0976Enfermedad de ParkinsonMedDRA version: 12.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2010-021394-37-ESCB Pharma SA349
已完成
不适用
Study of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus-E119 Non-insulin-dependent diabetes mellitus, without complicationsNon-insulin-dependent diabetes mellitus, without complicationsE119PER-032-04TAKEDA PHARMACEUTICALS,
进行中（未招募）
不适用
Ensayo multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de ACP-103 en el tratamiento de la psicosis en la enfermedad de Parkinson.A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson’s DiseasePsicosis en la enfermedad de Parkinson.Psychosis in Parkinson's DiseaseMedDRA version: 9.1Level: LLTClassification code 10037241Term: Psychosis NOSEUCTR2007-003051-36-ESAcadia Pharmaceuticals Inc280
进行中（未招募）
1 期
Estudio multicéntrico, randomizado, doble ciego en fase II, sobre la inmunogeneicidad de la vacuna -4x frente a placebo en pacientes infectados por VIH-1, que han mantenido una respuesta adecuada a TARSujetos positivos al VIH que se han mantenido estables con TAR durante los últimos seis meses, con una carga viral inferior a 50 copias/mL durante los últimos seis meses y un recuento de linfocitos CD4 =400x106/L, y que cumplen los demás criterios de inclusión y exclusión del protocolo.MedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infectionEUCTR2007-006302-13-ESBionor Immuno AS345